Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ.
Konecny GE, et al.
Gynecol Oncol. 2021 Jun;161(3):668-675. doi: 10.1016/j.ygyno.2021.03.015. Epub 2021 Mar 19.
Gynecol Oncol. 2021.
PMID: 33752918
Free PMC article.